HENLIUS: VOLUNTARY ANNOUNCEMENT - FIRST PATIENT IN MAINLAND CHINA HAS BEEN DOSED IN AN INTERNATIONAL MULTI-CENTER PHASE 3 CLINICAL STUDY OF THE COMBINATION OF HLX78 (LASOFOXIFENE) AND ABEMACICLIB COMPARED TO THE COMBINATION OF FULVESTRANT AND ABEMACICLIB FOR THE TR

HKEX · Dec 24 17:30

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

復宏漢霖：自願公告 - HLX78（拉索昔芬片）聯合阿貝西利對比氟維司群聯合阿貝西利用於局部晚期或轉移性乳腺癌的國際多中心3期臨床研究完成中國境內首例患者給藥

HENLIUS: VOLUNTARY ANNOUNCEMENT - FIRST PATIENT IN MAINLAND CHINA HAS BEEN DOSED IN AN INTERNATIONAL MULTI-CENTER PHASE 3 CLINICAL STUDY OF THE COMBINATION OF HLX78 (LASOFOXIFENE) AND ABEMACICLIB COMPARED TO THE COMBINATION OF FULVESTRANT AND ABEMACICLIB FOR THE TR

Risk Disclaimer

Statement